- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04976803
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein (ATM)
A Tissue Collection Study to Explore the Correlation Between ATM Genetic Alterations by Next-Generation Sequencing and ATM Loss-of-Protein Via IHC (ATR-ID Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W1G6AD
- Sarah Cannon Research UK
-
-
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 37104
- Oklahoma University
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients with identified ATM alterations will be potentially enrolled into this study in 1 of 3 patient populations
- Group A: Deceased patients with archival tumor tissue
- Group B: Living patients with archival tumor tissue
- Group C: Living patients without archival tumor tissue
Description
Inclusion Criteria:
- Patients must meet the following criteria in order to be included in the research study:
All patients (Groups A, B, and C) must meet the following criteria:
- Previous genetic testing of ATM genomic aberrations.
≥18 years of age.
All living patients (Groups B and C) must also meet the additional criteria:
Signed written informed consent to access archival tissue, if available.
All Group C patients must also meet the additional criteria:
- Provided signed written informed consent to collect a fresh core biopsy.
- Have a non-irradiated, biopsiable tumor site to allow sampling for analysis via IHC for loss of ATM protein.
Potentially eligible for REFMAL 721/ART0380C001:
- Have not received a previous treatment targeting the ATR/CHK1 pathway.
- If patients have a germline BRCA mutation or a cancer with a somatic BRCA mutation or which is HRD positive and for which there is an approved PARP inhibitor, patients should have received such treatment.
- Have an estimated life expectancy of ≥12 weeks, in the judgment of the investigator
- Advanced or metastatic cancer which is refractory to standard therapies, or for which no standard therapies exist, or for which the investigator feels no other active therapy is required for the duration of the study.
- Performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale
Exclusion Criteria:
There are no exclusion criteria for patients in Group A and Group B.
Group C patients who meet any of the following criteria will be excluded from study entry:
- Have a significant bleeding disorder or vasculitis or had a Grade 3 bleeding episode within 12 weeks prior to enrollment.
Presumed ineligible for enrollment to REFMAL 721/ART0380C001:
- Psychological, familial, sociological, or geographical conditions that that would compromise the patient's ability to adhere to future procedures likely in a Phase I protocol (such as REFMAL 721/ ART0380C001).
- Women who are pregnant, breast feeding, or who plan to become pregnant within the next 6 months.
- Men who plan to father a child within the next 6 months.
Have a serious concomitant systemic disorder that would compromise the patient's ability to adhere to a future protocol (REFMAL 721/ ART0380C001) including:
- One or more opportunistic HIV/AIDs-related infections within the past 12 months.
- Documented active or chronic infection with hepatitis B virus (positive hepatitis B surface antigen [+HBsAg]), or hepatitis C virus.
- Known history of clinical diagnosis of tuberculosis.
- Have had a malignancy prior to the current malignancy. Patients with carcinoma in situ of any origin and patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma), as judged by the medical monitor, are eligible for this study.
- Have evidence of interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic).
Have moderate or severe cardiovascular disease, such as the following:
- Have the presence of cardiac disease.
- Have valvulopathy that is severe, moderate, or deemed clinically significant.
- Have documented major electrocardiogram (ECG) abnormalities which are clinically significant.
- Have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids (patients receiving anticonvulsants are eligible).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group A
Deceased patients with archival tissue
|
ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
|
Group B
Living patients with archival tissue
|
ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
|
Group C
Living patients without archival tissue
|
ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with loss of ATM protein
Time Frame: 12 months
|
ATM protein expression levels from tumor tissue assessed by immunohistochemistry (IHC)
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of potential patients with loss of ATM protein eligible for study REFMAL 721/ART0380C001
Time Frame: 12 months
|
Patients in Group C are considered for enrolment into study REFMAL 721/ART0380C001 and must meet eligibility based on review of their medical records.
REFMAL 721/ART0380C001 is a phase I/IIa open-label trial to assess the safety, tolerability, and preliminary efficacy of the ATR kinase inhibitor, ART0380 administered as a monotherapy as well as in drug combinations with gemcitabine in patients with advanced or metastatic solid tumors.
|
12 months
|
Number of ATM genomic aberrations that lead to ATM LoP
Time Frame: 12 months
|
Identify types of ATM protein expression from tumor tissue assessed by immunohistochemistry (IHC)
|
12 months
|
Rate of loss of function (LoF) of the ATM gene in patients with genomic aberrations in the ATM gene
Time Frame: 12 months
|
ATM alterations identified using Next-Generation Sequencing(NGS) profiles
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Melissa Johnson, MD, Sarah Cannon Development Innovations
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ART0380C002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor, Unspecified, Adult
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Yantai LNC Biotechnology Singapore PTE. LTD.Recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisRecruiting
-
Pamela MunsterClovis Oncology, Inc.CompletedSolid Tumor, Unspecified, AdultUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedUnspecified Adult Solid TumorUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on Determination of ATM alteration status.
-
University GhentFund for Scientific Research, Flanders, BelgiumCompleted
-
Assistance Publique Hopitaux De MarseilleCompletedVenous Thromboembolism (VTE)France
-
Osmaniye Korkut Ata UniversityCompleted
-
Medical University of ViennaCompleted
-
University of OxfordUnknown
-
University of Alabama at BirminghamCompletedParkinson's Disease | Dystonia | TremorUnited States
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedAcid-Base Imbalance | Respiratory Acidosis | Respiratory AlkalosisItaly
-
424 General Military HospitalTerminated
-
RWTH Aachen UniversityUnknown
-
Centre Henri BecquerelUnknown